Anonymous ID: 528938 Dec. 19, 2020, 9:11 p.m. No.12100435   🗄️.is 🔗kun

WHERE DOES KLAUS OPERATE FROM DENMARK - MAYBE WE ARE MISSING SOMETHING HUGE? IT IS A CLUSTER FUCK OF EPIC PROPORTIONS?

THE DEEP STATE AND INTELLIGENCE SHADOW GOVERNMENT WHICH INVOLVES OVER 32 COUNTRIES AND CHINA IS ALL OVER IT. BIBLICAL IS NOT THE WORD, IT MUST BE TERMINATOR LEVEL SCORCHED EARTH LEVEL?

IT IS A MULTITUDE OF COUNTRIES AND THE INTELLIGENCE AGENCIES OF AT LEAST 14 COUNTRIES - JUST MY PREDICTION? SHADOW GOVERNMENT?

https://www.electrospaces.net/ <-this site is worth visiting because it has all the maps, locations and diagrams of a so many systems no one has yet heard of, we may be too late,?

https://privacysavvy.com/security/safe-browsing/detailed-five-eyes-9-eyes-14-eyes-concept-explanation/

https://en.wikipedia.org/wiki/Five_Eyes#Other_international_cooperatives

https://8kun.top/qresearch/res/12090838.html#12091333 <- Made notable

1) The Five Eyes (FVEY) is an intelligence alliance comprising Australia, Canada, New Zealand, the United Kingdom and the United States.[1] These countries are parties to the multilateral UKUSA Agreement, a treaty for joint cooperation in signals intelligence.

2) The Nine Eyes is a different arrangement that consists of the same members of Five Eyes working with Denmark, France, the Netherlands and Norway.

3) According to a document leaked by Edward Snowden, there is another working agreement amongst 14 nations officially known as SIGINT Seniors Europe, or "SSEUR".[91] These "14 Eyes" consist of the same members of Nine Eyes plus Belgium, Germany, Italy, Spain and Sweden

 

XKEYSCORE

 

DR News also reported that the heart of the new spy system is formed by XKEYSCORE, which was developed by the NSA and the existence of which was first revealed by The Guardian in June 2013.

 

The NSA's British counterpart GCHQ incorporated XKEYSCORE in its own system for processing bulk internet data codenamed TEMPORA and it can be assumed that the other Second Party partners (also known as the Five Eyes) also use this system, whether or not under a different codename.

Anonymous ID: 528938 Dec. 19, 2020, 9:28 p.m. No.12100609   🗄️.is 🔗kun   >>0630

>>12100505

This guy should to be publicly exhibited and shown that these treasonous behavioral actions have real consequences !!!

might be worth having a deep dive into where his money is coming from apart from his fake job?

Anonymous ID: 528938 Dec. 19, 2020, 9:50 p.m. No.12100817   🗄️.is 🔗kun   >>0885

>>12100728

CAPITAL LETTERS M.F.N = MOST FAVOURED NATIONS?

https://www.cms.gov/newsroom/fact-sheets/fact-sheet-most-favored-nation-model-medicare-part-b-drugs-and-biologicals-interim-final-rule

Nov 20, 2020

 

FACT SHEET: Most Favored Nation Model for Medicare Part B Drugs and Biologicals Interim Final Rule with Comment Period

The Centers for Medicare & Medicaid Services (CMS) is announcing a new payment model, the Most Favored Nation (MFN) Model (or the “MFN Model”), and issuing a corresponding Interim Final Rule with Comment Period (IFC). The MFN Model will lower prescription drug costs by paying no more for high-cost Medicare Part B drugs and biologicals (hereinafter called “drugs”) than the lowest price that drug manufacturers receive in other similar countries. The MFN Model will also pay providers a flat add-on amount for each dose of an MFN drug, instead of a percentage of each drug’s cost, removing the tie between drug cost and the add-on amount. Beneficiaries will pay lower coinsurance for these high-cost Part B drugs and will not pay coinsurance on the add-on payment. The MFN Model will require participation of Medicare providers and suppliers that receive separate Medicare Part B fee-for-service payment for the model’s included drugs, with certain exceptions, and begin nationally January 1, 2021.

One of the largest drivers of increasing Medicare spending is the growing prices for physician-administered separately payable Medicare Part B drugs, which have risen an average of 11.5 percent annually since 2015, with total spending of approximately $30 billion in 2019. These high, and increasing, costs are borne by Medicare beneficiaries and taxpayers and are the direct result of: (1) a lack of competitive market forces on Medicare Part B drug costs; and (2) an incentive system that pays hospitals, physicians (and non-physician practitioners), and other providers based on the volume of the drugs they use and the prices drug manufacturers set.

 

Executing on President Trump’s mandate to lower drug costs and recent Executive Order on Lowering Drug Prices by Putting America First (September 13, 2020) by announcing the MFN Model, CMS will introduce a most-favored-nation approach in calculating payment for Medicare Part B drugs. The MFN Model will test paying Part B drugs at comparable amounts to the lowest adjusted price[1] paid by any country in the Organisation for Economic Co-operation and Development (OECD)[2] that has a Gross Domestic Product (GDP) per capita that is at least 60 percent of the U.S. GDP per capita. The model will also test a redesign of the percentage add-on payment structure under Medicare Part B to remove incentives for use of higher-cost drugs through a flat per-dose add-on payment, and will include a financial hardship exemption for MFN participants.

CONTINUED IN ATTACHED LINK AT THE TOP OF THIS POST !!!

Anonymous ID: 528938 Dec. 19, 2020, 9:57 p.m. No.12100885   🗄️.is 🔗kun

>>12100817

SHORTER VERSION BECAUSE ANONS ARE GETTING LAZY AND NOT READING WALLS OF TEXT !!!

==

>CAPITAL LETTERS M.F.N = MOST FAVOURED NATIONS?

 

>https://www.cms.gov/newsroom/fact-sheets/fact-sheet-most-favored-nation-model-medicare-part-b-drugs-and-biologicals-interim-final-rule

 

>Nov 20, 2020

CAPITAL LETTERS M.F.N = MOST FAVOURED NATIONS? TRUMP E.O KICKS IN ON THE 1ST JANUARY 2021 THUS MAKING BIG PHARMA BANKRUPT?

----------------

https://www.cms.gov/newsroom/fact-sheets/fact-sheet-most-favored-nation-model-medicare-part-b-drugs-and-biologicals-interim-final-rule

Nov 20, 2020

https://twitter.com/realDonaldTrump/status/1340523944680583169

https://8kun.top/qresearch/res/12100076.html#q1210072